|
Related Party Transactions (Details Textual) (USD $)
|
1 Months Ended | 3 Months Ended | 0 Months Ended | 1 Months Ended | 6 Months Ended | 1 Months Ended | 6 Months Ended | 1 Months Ended | 6 Months Ended | 0 Months Ended | 1 Months Ended | 6 Months Ended | 12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Mar. 24, 2014
|
Apr. 28, 2014
|
Jun. 30, 2014
|
Jan. 10, 2014
Placement agent [Member]
|
Dec. 09, 2013
Placement agent [Member]
|
Aug. 07, 2012
Placement agent [Member]
|
Jun. 30, 2014
Placement agent [Member]
|
Jan. 31, 2014
Common Stock [Member]
|
Jun. 30, 2014
Common Stock [Member]
|
Jan. 31, 2014
Common Stock [Member]
Placement agent [Member]
|
Jan. 31, 2014
Warrant [Member]
|
Jun. 30, 2014
MSKCC [Member]
|
Jun. 30, 2013
MSKCC [Member]
|
Dec. 31, 2013
MSKCC [Member]
|
Dec. 31, 2012
MSKCC [Member]
Clinical Trial Agreement [Member]
|
Mar. 27, 2012
MSKCC [Member]
Clinical Trial Agreement [Member]
|
Sep. 04, 2013
SKI [Member]
License, Development and Commercialization Agreement [Member]
|
Jun. 19, 2011
SKI [Member]
License, Development and Commercialization Agreement [Member]
|
Jun. 30, 2014
SKI [Member]
License, Development and Commercialization Agreement [Member]
|
Dec. 31, 2013
SKI [Member]
License, Development and Commercialization Agreement [Member]
|
|
| Related Party Transactions (Textual) | ||||||||||||||||||||
| Amount paid under agreement in 2011 | $ 50,000 | |||||||||||||||||||
| Amount paid under agreement in 2012 | 200,000 | |||||||||||||||||||
| Amount paid under agreement in 2013 | 250,000 | |||||||||||||||||||
| Amount owed under agreement from 2011 to 2014 | 815,100 | |||||||||||||||||||
| Maintenance fees | 50,000 | 0 | 50,000 | |||||||||||||||||
| Placement agent services fees | 400,000 | |||||||||||||||||||
| Warrants issued to purchase common stock, shares | 68,976 | |||||||||||||||||||
| Common stock exercise price per share | $ 9.00 | $ 9 | ||||||||||||||||||
| Amount paid to each patient after Completing clinical trial | 31,185 | |||||||||||||||||||
| Start-up fee for clinical trial | 79,623 | |||||||||||||||||||
| Description of receivables of placement agent for services | Agreement entered in on December 9, 2013 had similar terms as the 2012 agreement, including a cash fee equal to 10% of the gross proceeds raised, a non-accountable expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company's Common Stock | Placement agent will receive (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering, and (c) reimbursement of $100,000 for legal expenses incurred by the placement agent. | ||||||||||||||||||
| Description of warrants receivables by placement | Warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued or issuable | The placement agent or its designees have also received warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued as part of the units sold in the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise of the B warrants included in such units. | ||||||||||||||||||
| Period of exercise of warrants | Within 6 months of the final closing of the 2012 common stock Offering | 5 years | ||||||||||||||||||
| Percentage of solicitation fee | 5.00% | |||||||||||||||||||
| Monthly fee for financial advisory services | 25,000 | 25,000 | ||||||||||||||||||
| Description of additional receivable by placement agent | The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the placement agent, the placement agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the placement agent will have the right to act as the Company's financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the August 7, 2012 engagement agreement. | |||||||||||||||||||
| Warrant held by placement agent to purchase common stock | 1,251,015 | |||||||||||||||||||
| Paid for research conducted | 189,537 | 129,850 | ||||||||||||||||||
| Royalty description | Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire. | |||||||||||||||||||
| Net payable to MSKCC | 189,537 | 81,185 | ||||||||||||||||||
| Common stock sold, Shares | 500 | 551,810 | 573,299 | |||||||||||||||||
| Warrants granted | 137,952 | |||||||||||||||||||
| Sale of Stock, Price Per Share | $ 6.00 | $ 9.00 | ||||||||||||||||||
| Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 6.00 | |||||||||||||||||||
| Gross proceeds from the sale of securities | 3,310,860 | |||||||||||||||||||
| Gross proceeds received in Offering | $ 6,636,720 | |||||||||||||||||||
| Aggregate offering amount of securities sold to investors | The Company will pay MLV in cash, upon the sale of common stock pursuant to the Sales Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock. On April 28, 2014 the Company issued 500 shares and received net proceeds of $6,000 under the Sales Agreement with MLV. | Aggregate offering amount of securities sold to investors was increased from $6,000,000 to $6,636,720 in order to cover over-allotments | ||||||||||||||||||